47 results on '"Mansoor, W."'
Search Results
2. 1249P Older patients experience similar toxicity and survival outcomes to FLOT chemotherapy compared to younger patients
3. PD-2 EMERGE: A multi-centre, non-randomised, single-arm phase II study investigating domatinostat plus avelumab in patients with previously treated advanced mismatch repair-proficient oesophagogastric and colorectal adenocarcinoma
4. Older patients enrolling in early phase clinical trials; higher rates of sarcopenia, but no increase in toxicity
5. PD-0541: Transfer learning for automatic sarcopenia evaluation at T12 vertebral level
6. 589P The impact of sarcopenia in patients enrolled in early phase cancer trials
7. LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
8. Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study
9. Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study
10. Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062
11. Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
12. Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study
13. Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS)
14. Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): Real-world findings from two European neuroendocrine tumour society centres of excellence
15. Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreatobiliary cancers: A UK study
16. Prognostic importance of lymph node (LN) yield after curative resection of gastroenteropancreatic neuroendocrinetumours (GEP NETs)
17. EGFR amplification (amp) and survival in the REAL-3 trial
18. Association of sarcopenia with dose-limiting toxicties and survival in oesophageal adenocarcinoma treated with neoadjuvant chemotherapy
19. Assessment of anorexia and weight loss in newly diagnosed upper gastrointestinal cancer patients with localised and metastatic disease, using the functional assessment of anorexia cachexia therapy anorexia/cachexia subscale (FAACT A/CS)
20. TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer
21. 30-day mortality associated with systemic anti-cancer therapy (SACT) in gastrointestinal malignancies: The Christie experience
22. Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)
23. KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
24. Neoadjuvant FLOT: Real world toxicity from a specialist UK centre
25. The incidence, diagnostic pathway and management of pulmonary carcinoid tumours in the UK: results from the National Lung NET pathway (‘LEAP’) Project
26. Mixed adeno-neuroendocrine carcinoma (MANEC) of the gastroenteropancreatic (GEP) tract: A multicentre retrospective study
27. Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): Incidence and impact on quality of life
28. Carcinoid syndrome: Patient outcomes from a European Neuroendocrine Tumour Society (ENETs) centre of excellence
29. A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB
30. Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): Time to maximum response and optimal treatment duration
31. Thromboembolic complications in patients with oesophagogastric adenocarcinoma undergoing preoperative chemotherapy
32. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification
33. 3: Germline sequencing of DIPNECH patients reveals a heterogeneous disease with novel SNVs in genes that are somatically mutated in other neuroendocrine malignancies
34. A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948)
35. Prognostic significance of neutrophil to lymphocyte ratio (NLR) in patients (pts) with resectable gastric/gastroesophageal junction (GOJ) adenocarcinoma undergoing perioperative chemotherapy
36. Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study
37. Multicentre evaluation of the role of Gallium DOTA-PET (GaPET) imaging in well differentiated bronchial carcinoids (BC): Impact on patients' (pts) management
38. Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery
39. 2201 Peri-operative chemotherapy ± bevacizumab for resectable gastro-oesophageal adenocarcinoma: Results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948)
40. P-066 S-1 in combination with epirubicin and oxaliplatin (EOS) in Caucasian patients (pts) with advanced or metastatic gastric cancer (AGC): Results of a phase I study
41. P-123 Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery
42. Fgfr Inhibitor and Chemotherapy in Gastric Cancer (Facing): Phase I Results from an Ecmc Combinations Alliance Phase I/II Trial of Azd4547 in Combination with Cisplatin and Capecitabine (Cx)
43. Phase III Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of Gefitinib versus Placebo in Esophageal Cancer Progressing after Chemotherapy, COG (Cancer Oesophagus Gefitinib)
44. Does Specialist Centre Histopathology Review of Gastrointestinal Neuroendocrine Tumours Affect Clinical Management?
45. 6590 POSTER Phase Ma Study of TP300 as 1st-line Monotherapy in Patients With Advanced Gastric (GC) or Gastro-oesophageal Junction (GOJ) Carcinoma
46. A 3year retrospective audit of chromogranin results in a tertiary referral centre: Is Chromogranin B measurement necessary?
47. Clinical Oncology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.